A comparison of single‐dose oral fluconazole with 3‐day intravaginal clotrimazole in the treatment of vaginal candidiasis

Summary. A total of 369 women with clinical and mycological evidence of vaginal candidiasis received treatment, after random allocation, with either a single oral 150‐mg dose of fluconazole (188 women) or 200 mg of intravaginal clotrimazole given daily for 3 consecutive days (181 women). They were assessed at 5–16 days and again at 27–62 days after treatment. Candida species were completely eradicated from the vagina in 72% of the fluconazole group and in 62% of the clotrimazole group at the long‐term assessment (P=0·07). Favourable clinical responses were obtained in 99% of the fluconazole group and in 97% of the clotrimazole group at the short‐term assessment and in 93% and 84% respectively at the long‐term assessment when there was a significant advantage for fluconazole treatment (P=0·02). Symptoms in patients receiving fluconazole were relieved more rapidly (P<0·001). Treatment‐related side‐effects were few and minor in both groups. It is concluded that treatment of vaginal candidiasis with fluconazole, as a single oral dose, was more effective in the long term, relieved symptoms more rapidly, and was as safe as treatment with intravaginal clotrimazole.

[1]  J. Sobel,et al.  Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. , 1986, Journal of Infectious Diseases.

[2]  G. Cauwenbergh,et al.  Itraconazole (R 51 211): A clinical review of its antimycotic activity in dermatology, gynecology, and internal medicine , 1986 .

[3]  Tooley Pj Patient and doctor preferences in the treatment of vaginal candidosis. , 1985 .

[4]  P. Troke,et al.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes , 1985, Antimicrobial Agents and Chemotherapy.

[5]  P. Tooley Patient and doctor preferences in the treatment of vaginal candidosis. , 1985, The Practitioner.

[6]  Jeanne Hawkins Tyle Ketoconazole; Mechanism of Action, Spectrum of Activity, Pharmacokinetics, Drug Interactions, Adverse Reactions and Therapeutic Use , 1984 .

[7]  P. Bennett,et al.  European Ethical Review Committee: the experience of an international ethics committee reviewing protocols for drug trials. , 1984, British medical journal.

[8]  J. V. van Cutsem,et al.  Treatment of vaginal candidosis with oral ketoconazole. , 1983, European journal of obstetrics, gynecology, and reproductive biology.

[9]  D. Stevens,et al.  Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.

[10]  J. García-tamayo,et al.  Human genital candidiasis: histochemistry, scanning and transmission electron microscopy. , 1982, Acta cytologica.

[11]  A. Rogers,et al.  Recurrent Vaginal Candidiasis: Importance of an Intestinal Reservoir , 1977 .

[12]  A. Rogers,et al.  Recurrent vaginal candidiasis. Importance of an intestinal reservoir. , 1977, JAMA.